News
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial ...
Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies Partnership builds on long-term relationship to provide Quell with additional ...
London, UK – June 9 2023 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system today ...
Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell ...
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results